Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-27T01:21:22.186Z Has data issue: false hasContentIssue false

Aesthesioneuroblastoma

Published online by Cambridge University Press:  29 June 2007

Venkata N. Koka
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Morbize Julieron
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Jean Bourhis
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Francois Janot
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Anne Marie Le Ridant
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Patrick Marandas
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Bernard Luboinski
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
Guy Schwaab*
Affiliation:
Department of Head and Neck Surgery, Institut Gustave Roussy, 94805 Villejuif, France.
*
Address for correspondence: Dr Guy Schwaab, M.D., Chief of Unit-Head and Neck Surgery, Institut Gustave Roussy, 39, rue Camille Desmoulins, 94805 Villejuif, France. Fax: 331 42115273

Abstract

Forty patients were treated or followed up for aesthesioneuroblastoma between 1980 and 1995 at Institut Gustave Roussy, France. There were three T1; seven T2, 15 T3 and 15 T4 lesions. The cervical metastatic rate at presentation was 18 per cent. Distant metastases were detected by bone marrow biopsy and bone scan in three patients at presentation. Treatment modalities included surgery alone in eight patients, radiotherapy alone in three patients, combined modality surgery plus radiotherapy in 11 patients, chemotherapy alone in two patients, chemotherapy plus radiotherapy in 10 patients, and multimodality therapy chemotherapy plus surgery plus radiotherapy in six patients.

The five-year survival rate was 51 per cent. Multimodality treatment offered better survival (63 per cent at five years) and disease-free interval (54 months). Overall local, regional, and distant failure rates were 58 per cent, 15 per cent and 40 per cent respectively. Distant metastases commonly occurred in bone (82 per cent). Cervical metastasis was an unfavourable prognostic indicator (0 per cent survival at two years).

In conclusion, aesthesioneuroblastoma is sensitive to chemotherapy and radiotherapy. Multimodality therapy should be used initially.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Al Ahwal, M., Jha, N., Nabholtz, J. M., Hugh, J., Birchall, J., Nguyen, G. K. (1993) Olfactory neuroblastoma: report of a case associated with inappropriate antidiuretic hormone secretion. Journal of Otolaryngology 23: 437439.Google Scholar
Arnesen, M. A., Scheithauer, B. W., Freeman, S. (1994) Cushing syndrome secondary to olfactory neuroblastoma. Ultrastructural Pathology 18: 6168.CrossRefGoogle ScholarPubMed
Bailey, B. J., Barton, S. (1975) Olfactory neuroblastoma: Management and prognosis. Archives of Otolaryngology 101: 15.CrossRefGoogle ScholarPubMed
Beitler, J. J., Fass, D. E., Brenner, H. A., Huvos, A., Harrison, L. B., Leibel, S. A., Fukus, Z. (1991) Esthesioneuroblas-toma: is there a role for elective neck treatment. Head and Neck 13: 321326.CrossRefGoogle Scholar
Berger, L., Luc, R. (1924) Esthesioneuroepithelioma olfactif. Bulletin de I'Association Francaise pour I'Etude du Cancer 13: 410421.Google Scholar
Davis, R. E., Weisser, M. C. (1992) Esthesioneuroblastoma and neck metastases. Head and Neck 14: 477482.CrossRefGoogle Scholar
Eden, B. V., Debo, R. F., Larner, J. M., Kelly, M. D., Levine, P. A., Stewart, F. M., Cantrell, R. W., Constable, W. C. (1994) Esthesioneuroblastoma. Long term outcome and patterns of failure. The University of Virginia Experience. Cancer 73: 25562562.3.0.CO;2-S>CrossRefGoogle ScholarPubMed
Foote, R. L., Morita, A., Ebersold, M. J., Oslen, K. D., Lewis, J. E., Quast, L. M., Ferguson, J. A., O'Fallon, W. M. (1993) Esthesioneuroblastoma: the role of adjuvant radiation therapy. International Journal of Radiation Oncology Biology and Physics 27: 835842.CrossRefGoogle ScholarPubMed
Jekunen, A. P., Kairemo, K. J. A., Lehtonen, H. P., Kajanti, M. J. (1996) Treatment of olfactory neuroblastoma. A report of 11 cases. American Journal of Clinical Oncology 19: 7578.CrossRefGoogle ScholarPubMed
Kadish, S., Goodman, M., Wang, C. C. (1976) Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 37: 15711576.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Kaplan, E. L., Meijer, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 53: 457481.CrossRefGoogle Scholar
Levine, P. A., McClean, C., Cantrell, R. W. (1986) Esthesio-neuroblastoma: The University of Virginia Experience 1960–1985. Laryngoscope 96: 742746.CrossRefGoogle Scholar
Mills, S. E., Frierson, H. F. (1985) Olfactory neuroblastoma – a clinicopathologic study of cases. American Journal of Surgical Pathology 9: 317327.CrossRefGoogle Scholar
Oslen, K. D., DeSanto, L. W. (1983) Olfactory neuroblastoma: biologic and clinical behavior. Archives of Otolaryngology 109: 797802.Google Scholar
Peto, R., Pike, M. C. (1973) Conservatism in the approximation ∑(O-E)2/E in the log-rank test for survival data or tumor incidence data. Biometrics 29: 579584.CrossRefGoogle ScholarPubMed
Schenck, L., Ogura, J. H. (1972) Esthesioneuroblastoma: an enigma in diagnosis, a dilemma in treatment. Archives of Otolaryngology 96: 322324.CrossRefGoogle ScholarPubMed
Schwaab, G., Micheau, C., Pacheco, L., Marandas, P., Domenge, C., Richard, J. M., Wibault, P. (1988) Olfactory esthesioneuroblastoma: a report of 40 cases. Laryngoscope 98: 872876.CrossRefGoogle Scholar